TP53 and acute myeloid leukemia: There was no typical driver alteration like TP53 or FLT3 mutations and no typical cytogenetic aberrations of CK-AML like del(5q), -7/del(7q), or del(17p) present in this patient, which could provide a proliferative advantage or even initiate leukemogenesis.